Buscar
Biofrontera Inc
BFRIAñadir a la lista de seguimiento
1.170USD
-0.060-4.88%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
13.89MCap. mercado
PérdidaP/E TTM
Más Datos de Biofrontera Inc Compañía
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Información de Biofrontera Inc
Símbolo de cotizaciónBFRI
Nombre de la empresaBiofrontera Inc
Fecha de salida a bolsaOct 14, 2021
Director ejecutivoLuebbert (Hermann)
Número de empleados92
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 14
Dirección120 Presidential Way,
CiudadWOBURN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01801
Teléfono17812451325
Sitio Webhttps://www.biofrontera-us.com/
Símbolo de cotizaciónBFRI
Fecha de salida a bolsaOct 14, 2021
Director ejecutivoLuebbert (Hermann)
Ejecutivos de Biofrontera Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
311.14K
+6.73%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
175.00K
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
311.14K
+6.73%
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
175.00K
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Biofrontera Inc?
Los cinco principales accionistas de Biofrontera Inc son: Prof. Dr. Hermann Luebbert, Ph.D.
¿Cuántas instituciones poseen acciones de Biofrontera Inc (BFRI)?
A fecha de 2026Q1, 37 instituciones poseen acciones de Biofrontera Inc, con un valor de mercado combinado de aproximadamente 2.75M, lo que representa el 22.90% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -276665.00.